Passage Bio Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs and private third-party payors. Its market includes manufacturers of drugs, devices, biological, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. The company operates within market segments such as federal healthcare programs, private third-party payors, Medicaid, state programs, and covered entities under HIPAA regulations.
Passage Bio Receives FDA Endorsement to Broaden upliFT-D Trial for PBFT02 to Encompass FTD-C9orf72 PatientsPassage Bio, a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, has recently secured positive feedback from the U.S. Food and Drug Administration (FDA) regarding the expansion of its upliFT-D clinical trial. This pivotal development was the result of the Type C meeting process with the FDA, which has endorsed Passage Bio s proposed plans to include patients with Frontotemporal Dementia (FTD) associated with C9orf72 gene mutations in their ongoing study of PBFT02.PBFT02 is an innovative gene therapy aimed at addressing th...
Passage Bio to Present at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPHILADELPHIA, April 22, 2024 - Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, has announced its participation at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The event is set to take place virtually on Monday, April 29, 2024, at 9:00 a.m. ET. Passage Bio s CEO, William Chou, M.D., and the senior vice president of technical operations, Eden Fucci, will be representing the company and engaging in a virtual fireside chat during the summit.Passage Bio, a leading genetic medicin...
Passage Bio Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs and private third-party payors. Its market includes manufacturers of drugs, devices, biological, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. The company operates within market segments such as federal healthcare programs, private third-party payors, Medicaid, state programs, and covered entities under HIPAA regulations.
Sources:
Passage Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Passage Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Passage Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
